{
    "symbol": "APTO",
    "quarter": 2,
    "year": 2022,
    "date": "2022-08-02 21:00:04",
    "content": " It's gratifying to see the continued progress with additional complete remissions during the first half of this year, to see the breadth of complete remissions in patients with highly adverse mutations for other agents already have failed, to see all the newer patients going on study recently and to see how these findings got our path toward registration studies and suggest ample commercial opportunities through multiple AML target populations and our Chief Medical Officer, Dr. Bejar will expand on these concepts in a few moments when he provides our clinical overview of 239."
}